Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
35.98
-0.92 (-2.51%)
Streaming Delayed Price
Updated: 11:22 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunocore Holdings Plc ADR
< Previous
1
2
3
4
5
Next >
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
August 09, 2024
Via
Benzinga
Immunocore reports second quarter financial results and provides a business update
August 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
3 Small-Cap Stocks with Significant Growth Potential
August 06, 2024
As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love.
Via
InvestorPlace
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
August 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
July 10, 2024
Via
Benzinga
Analyst Expectations For Immunocore Hldgs's Future
May 24, 2024
Via
Benzinga
Where Immunocore Hldgs Stands With Analysts
April 29, 2024
Via
Benzinga
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
April 11, 2024
Via
Benzinga
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Key Takeaways From Immunocore Hldgs Analyst Ratings
February 29, 2024
Via
Benzinga
Immunocore Hldgs's Earnings: A Preview
February 27, 2024
Via
Benzinga
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Immunocore reports first quarter financial results and provides a business update
May 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
April 04, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Immunocore presented two posters at CROI 2024
March 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
March 01, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
February 22, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Prices Upsized Convertible Senior Notes Offering
January 30, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
January 29, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.